Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew F Brown

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|February 1, 2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune DiseasesBrian S Gerstenberger, Catherine Ambler, Eric P Arnold, et al.
Journal of Medicinal Chemistry|November 7, 2014
Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitorsMark E Flanagan, Joseph A Abramite, Dennis P Anderson, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
The identification of orally bioavailable thrombopoietin agonistsMichael J Munchhof, Amy S Antipas, Laura C Blumberg, et al.
Journal of Medicinal Chemistry|November 26, 2010
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejectionMark E Flanagan, Todd A Blumenkopf, William H Brissette, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel CCR1 antagonists with improved metabolic stabilityMatthew F Brown, Mike Avery, William H Brissette, et al.
ACS Chemical Biology|July 9, 2016
Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in MetabolismKay Ahn, Markus Boehm, Matthew F Brown, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2007
Piperazinyl CCR1 antagonists--optimization of human liver microsome stabilityMatthew F Brown, Kevin B Bahnck, Laura C Blumberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2018
Delineating the role of cooperativity in the design of potent PROTACs for BTKAdelajda Zorba, Chuong Nguyen, Yingrong Xu, et al.
ACS Chemical Biology|October 30, 2016
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|February 1, 2017
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in HumansAtli Thorarensen, Martin E Dowty, Mary Ellen Banker, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune DiseasesBrian S Gerstenberger, Catherine Ambler, Eric P Arnold, et al.
Journal of Medicinal Chemistry|November 7, 2014
Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitorsMark E Flanagan, Joseph A Abramite, Dennis P Anderson, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
The identification of orally bioavailable thrombopoietin agonistsMichael J Munchhof, Amy S Antipas, Laura C Blumberg, et al.
Journal of Medicinal Chemistry|November 26, 2010
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejectionMark E Flanagan, Todd A Blumenkopf, William H Brissette, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel CCR1 antagonists with improved metabolic stabilityMatthew F Brown, Mike Avery, William H Brissette, et al.
ACS Chemical Biology|July 9, 2016
Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in MetabolismKay Ahn, Markus Boehm, Matthew F Brown, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2007
Piperazinyl CCR1 antagonists--optimization of human liver microsome stabilityMatthew F Brown, Kevin B Bahnck, Laura C Blumberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2018
Delineating the role of cooperativity in the design of potent PROTACs for BTKAdelajda Zorba, Chuong Nguyen, Yingrong Xu, et al.
ACS Chemical Biology|October 30, 2016
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective InhibitionJean-Baptiste Telliez, Martin E Dowty, Lu Wang, et al.
Pageof 4